4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
10 janv. 2025 08h00 HE
|
4D Molecular Therapeutics, Inc.
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter...
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
10 janv. 2025 08h00 HE
|
4D Molecular Therapeutics, Inc.
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical...
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
16 déc. 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and...
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
14 nov. 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
13 nov. 2024 16h05 HE
|
4D Molecular Therapeutics, Inc.
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse...
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
23 sept. 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
18 sept. 2024 16h05 HE
|
4D Molecular Therapeutics, Inc.
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data In broad population...
4DMT Announces Presentations at Upcoming Retina Conferences
05 sept. 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
03 sept. 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
27 août 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
Company to highlight 4D-150 product development strategy and Phase 1/2 PRISM clinical trial data in wet age-related macular degeneration (wet AMD), including longest available interim follow-up data ...